ADA Scientific Sessions 2026 Abstract

Understanding the Lived Experiences of Dosing Practices among People Living with Obesity (PwO) Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Weight Loss (WL): A U.S. Qualitative Study

By Vanita Aroda, Michael Donnelly-Boylen, Zeb I. Saeed, Jannie V. Laursen

Study in peoplePopulations

The paper

Vanita Aroda, Michael Donnelly-Boylen, Zeb I. Saeed, Jannie V. Laursen

Boston

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 2614-P

doi.org/10.2337/db26-2614-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety